166 related articles for article (PubMed ID: 30687751)
21. Immunity to tetanus: tetanus antitoxin and anti-BIIb in human sera.
German-Fattal M; Bizzini B; German A
J Biol Stand; 1987 Jul; 15(3):223-30. PubMed ID: 3611114
[TBL] [Abstract][Full Text] [Related]
22. Duration of maternally derived immunity to tetanus and response in newborn foals given tetanus antitoxin.
Liu IK; Brown SL; Kuo J; Neeley DP; Feeley JC
Am J Vet Res; 1982 Nov; 43(11):2019-22. PubMed ID: 7181201
[TBL] [Abstract][Full Text] [Related]
23. [Production and immunogenicity analysis of conformation-stable fragment-C mutant of tetanus toxin].
Yu R; Hou L; Liu S; Yu C; Zhang X; Liu Y; Chen W
Sheng Wu Gong Cheng Xue Bao; 2011 Feb; 27(2):226-32. PubMed ID: 21650047
[TBL] [Abstract][Full Text] [Related]
24. Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.
Yu YZ; Liu S; Ma Y; Gong ZW; Wang S; Sun ZW
Hum Vaccin Immunother; 2014; 10(7):1874-9. PubMed ID: 25424795
[TBL] [Abstract][Full Text] [Related]
25. Antibodies against the light chain of tetanus toxin in human sera.
Lin CS; Habig WH; Hardegree MC
Infect Immun; 1985 Jul; 49(1):111-5. PubMed ID: 2409006
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of a recombinant tetanus toxin subunit vaccine.
Liu FJ; Shi DY; Li ZY; Lu JS; Wang R; Pang XB; Yang ZX; Yu YZ
Toxicon; 2020 Nov; 187():75-81. PubMed ID: 32889026
[TBL] [Abstract][Full Text] [Related]
27. Elevated antitoxin titers in a man with generalized tetanus.
Pryor T; Onarecker C; Coniglione T
J Fam Pract; 1997 Mar; 44(3):299-303. PubMed ID: 9071251
[TBL] [Abstract][Full Text] [Related]
28. Production, characterization and applications of a tetanus toxin specific monoclonal antibody T-62.
Petrušić V; Zivković I; Stojanović M; Stojićević I; Marinković E; Dimitrijević L
Acta Histochem; 2012 Sep; 114(5):480-6. PubMed ID: 21975055
[TBL] [Abstract][Full Text] [Related]
29. Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines.
Qazi O; Sesardic D; Tierney R; Söderbäck Z; Crane D; Bolgiano B; Fairweather N
Infect Immun; 2006 Aug; 74(8):4884-91. PubMed ID: 16861677
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, heat stability and safety of intranasally administered Bacillus subtilis spore or vegetative cell vaccines expressing tetanus toxin fragment C.
Lee S; Belitsky BR; Brown DW; Brinker JP; Kerstein KO; Herrmann JE; Keusch GT; Sonenshein AL; Tzipori S
Vaccine; 2010 Sep; 28(41):6658-65. PubMed ID: 20709005
[TBL] [Abstract][Full Text] [Related]
31. Comparative Immunogenicity of the Tetanus Toxoid and Recombinant Tetanus Vaccines in Mice, Rats, and Cynomolgus Monkeys.
Yu R; Fang T; Liu S; Song X; Yu C; Li J; Fu L; Hou L; Xu J; Chen W
Toxins (Basel); 2016 Jun; 8(7):. PubMed ID: 27348002
[TBL] [Abstract][Full Text] [Related]
32. Validation of the combined toxin-binding inhibition test for determination of neutralizing antibodies against tetanus and diphtheria toxins in a vaccine field study in Viet Nam.
Hong HA; Ke NT; Nhon TN; Thinh ND; van der Gun JW; Hendriks JT; Kreeftenberg JG
Bull World Health Organ; 1996; 74(3):275-82. PubMed ID: 8789926
[TBL] [Abstract][Full Text] [Related]
33. Clinical tetanus despite a protective level of toxin-neutralizing antibody.
Passen EL; Andersen BR
JAMA; 1986 Mar; 255(9):1171-3. PubMed ID: 2868135
[No Abstract] [Full Text] [Related]
34. Co-expression of tetanus toxin fragment C in Escherichia coli with thioredoxin and its evaluation as an effective subunit vaccine candidate.
Yu YZ; Gong ZW; Ma Y; Zhang SM; Zhu HQ; Wang WB; Du Y; Wang S; Yu WY; Sun ZW
Vaccine; 2011 Aug; 29(35):5978-85. PubMed ID: 21718736
[TBL] [Abstract][Full Text] [Related]
35. Sublingual immunization with an engineered Bacillus subtilis strain expressing tetanus toxin fragment C induces systemic and mucosal immune responses in piglets.
Amuguni H; Lee S; Kerstein K; Brown D; Belitsky B; Herrmann J; Keusch G; Sonenshein A; Tzipori S
Microbes Infect; 2012 May; 14(5):447-56. PubMed ID: 22198093
[TBL] [Abstract][Full Text] [Related]
36. A Dual Strategy-In Vitro and In Silico-To Evaluate Human Antitetanus mAbs Addressing Their Potential Protective Action on TeNT Endocytosis in Primary Rat Neuronal Cells.
Lima CP; Barreiros GM; Oliveira ASA; de Souza MM; Manieri TM; Moro AM
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891974
[TBL] [Abstract][Full Text] [Related]
37. [Immunological protection against tetanus].
German A; Fattal-German M; Bizzini B
Bull Acad Natl Med; 1987 Jun; 171(6):735-41. PubMed ID: 3325148
[No Abstract] [Full Text] [Related]
38. Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule.
Volk WA; Bizzini B; Snyder RM; Bernhard E; Wagner RR
Infect Immun; 1984 Sep; 45(3):604-9. PubMed ID: 6205994
[TBL] [Abstract][Full Text] [Related]
39. A single-dose cytomegalovirus-based vaccine encoding tetanus toxin fragment C induces sustained levels of protective tetanus toxin antibodies in mice.
Tierney R; Nakai T; Parkins CJ; Caposio P; Fairweather NF; Sesardic D; Jarvis MA
Vaccine; 2012 Apr; 30(20):3047-52. PubMed ID: 22414558
[TBL] [Abstract][Full Text] [Related]
40. [Determination of tetanus toxin and toxoid by ELISA using monoclonal antibodies].
Burkin MA; Sviridov VV; Perelygina OV
Prikl Biokhim Mikrobiol; 2004; 40(4):478-84. PubMed ID: 15455723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
